AlloVir (ALVR) Competitors $2.58 -0.09 (-3.37%) As of 07/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVR vs. OSTX, PEPG, ATNM, ATRA, XCUR, ADVM, ALGS, IPA, STTK, and MRSNShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include OS Therapies (OSTX), PepGen (PEPG), Actinium Pharmaceuticals (ATNM), Atara Biotherapeutics (ATRA), Exicure (XCUR), Adverum Biotechnologies (ADVM), Aligos Therapeutics (ALGS), ImmunoPrecise Antibodies (IPA), Shattuck Labs (STTK), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Its Competitors OS Therapies PepGen Actinium Pharmaceuticals Atara Biotherapeutics Exicure Adverum Biotechnologies Aligos Therapeutics ImmunoPrecise Antibodies Shattuck Labs Mersana Therapeutics OS Therapies (NYSE:OSTX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings. Is OSTX or ALVR more profitable? OS Therapies' return on equity of 0.00% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% AlloVir N/A -71.03%-61.27% Which has preferable valuation & earnings, OSTX or ALVR? OS Therapies is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79M-$0.86-2.22AlloVirN/AN/A-$190.42M-$20.23-0.13 Do analysts rate OSTX or ALVR? OS Therapies presently has a consensus target price of $18.00, indicating a potential upside of 842.41%. Given OS Therapies' stronger consensus rating and higher possible upside, equities research analysts clearly believe OS Therapies is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in OSTX or ALVR? 66.1% of AlloVir shares are owned by institutional investors. 13.8% of OS Therapies shares are owned by company insiders. Comparatively, 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to OSTX or ALVR? In the previous week, OS Therapies had 6 more articles in the media than AlloVir. MarketBeat recorded 6 mentions for OS Therapies and 0 mentions for AlloVir. OS Therapies' average media sentiment score of 0.46 beat AlloVir's score of 0.00 indicating that OS Therapies is being referred to more favorably in the media. Company Overall Sentiment OS Therapies Neutral AlloVir Neutral SummaryOS Therapies beats AlloVir on 9 of the 13 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.01M$201.90M$5.54B$8.87BDividend YieldN/AN/A5.39%4.10%P/E Ratio-0.13N/A26.1719.90Price / SalesN/A240.67414.67113.66Price / CashN/A22.4436.1356.90Price / Book0.095.678.055.38Net Income-$190.42M-$96.61M$3.15B$248.50M7 Day Performance3.61%2.97%1.85%2.97%1 Month Performance-11.03%4.31%4.81%6.02%1 Year Performance-84.74%15.58%34.86%20.39% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$2.58-3.4%N/A-84.1%$13.01MN/A-0.13110Gap UpOSTXOS Therapies2.611 of 5 stars$1.70-4.5%$18.00+958.8%N/A$47.77MN/A-1.98N/ANews CoverageAnalyst ForecastPEPGPepGen2.8935 of 5 stars$1.39-4.1%$7.67+451.6%-93.9%$47.44MN/A-0.4430ATNMActinium Pharmaceuticals2.3337 of 5 stars$1.52+1.3%$4.00+163.2%N/A$47.42M$81K-1.0930News CoverageATRAAtara Biotherapeutics4.3989 of 5 stars$7.88-0.8%$17.75+125.3%-6.7%$47.33M$128.94M-2.12330XCURExicure1.9881 of 5 stars$6.50-13.0%N/A+1,835.9%$47.19M$500K-1.3550Earnings ReportGap DownADVMAdverum Biotechnologies4.3304 of 5 stars$2.23-0.9%$26.40+1,083.9%-67.3%$47M$1M-0.35190ALGSAligos Therapeutics4.2166 of 5 stars$7.18-4.9%$70.00+874.9%-19.9%$46.16M$3.27M-0.4190Positive NewsIPAImmunoPrecise Antibodies2.5169 of 5 stars$0.96-4.5%$4.00+316.6%+9.6%$45.99M$24.00M-0.8380Upcoming EarningsGap UpSTTKShattuck Labs3.3429 of 5 stars$1.01+5.5%$7.50+642.6%-79.6%$45.84M$4.61M-0.73100News CoverageMRSNMersana Therapeutics3.8223 of 5 stars$0.34-6.9%$5.20+1,426.7%-85.8%$45.60M$40.50M-0.58150News Coverage Related Companies and Tools Related Companies OSTX Alternatives PEPG Alternatives ATNM Alternatives ATRA Alternatives XCUR Alternatives ADVM Alternatives ALGS Alternatives IPA Alternatives STTK Alternatives MRSN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALVR Stock Alerts